Alvaro Morales, MD | Authors

Commentary (Morales): BCG Immunotherapy for Transitional-Cell Carcinoma in Situ of the Bladder

October 01, 1995

Very few people have the level of expertise Dr. Lamm does with the use of bacillus Calmette-Guérin (BCG) for the treatment of superficial bladder cancer. His enthusiasm is based on a large, solid experience with the vaccine. He has pushed the therapeutic effectiveness of BCG to new levels and has reviewed the world literature on the subject frequently and conscientiously. The current review covers most areas of interest in depth. A few key points deserve emphasis, however.